US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

6.28

-0.0300-0.48%

Post-market: 6.280.00000.00%16:10 EST

Volume:552.21K

Turnover:3.43M

Market Cap:458.36M

PE:-2.51

High:6.42

Open:6.32

Low:6.03

Close:6.31

52wk High:10.99

52wk Low:1.45

Shares:72.99M

Float Shares:45.01M

Volume Ratio:0.87

T/O Rate:1.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5000

EPS(LYR):-3.0934

ROE:-80.69%

ROA:-44.66%

PB:3.79

PE(LYR):-2.03

Loading ...

Overview Company News Filings

Lexeo Therapeutics Announces Head of Research Transition

Lexeo Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Narinder Pal Bhalla

Lexeo Therapeutics Announces Transition Compensation Agreement for Dr. Adler

Lexeo Therapeutics to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference

BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare

BUZZ-Lexeo rises as it announces leadership changes

Press Release: Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Cantor Fitzgerald

Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright

Raymond James Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results

Lexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial

MT Newswires Live

Lexeo Therapeutics Inc trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM

Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases

Lexeo Therapeutics Reports Positive Interim Results for LX2020 in PKP2-Associated Cardiomyopathy Trial

Lexeo Therapeutics Announces Positive Interim Phase I/Ii Data for Lx2020 for the Treatment of Pkp2-Associated Arrhythmogenic Cardiomyopathy

THOMSON REUTERS

Lexeo Therapeutics Inc: Lx2020 Generally Well Tolerated Across Ten Participants With No Clinically Significant Complement Activation

THOMSON REUTERS

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LXEO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":6.28,"timestamp":1771362000000,"preClose":6.31,"halted":0,"volume":552212,"hourTrading":{"tag":"盘后","latestPrice":6.28,"preClose":6.28,"latestTime":"16:10 EST","volume":12791,"amount":80327.48,"timestamp":1771362604707,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004754358161648076,"floatShares":45005000,"shares":72987327,"eps":-2.5,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"02-17 16:19:41 EST","open":6.32,"high":6.42,"low":6.03,"amount":3427975.578126,"amplitude":0.061807,"askPrice":6.69,"askSize":10,"bidPrice":5.95,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-2.5,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771376400000},"marketStatusCode":4,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":6.31,"preHourTrading":{"tag":"盘前","latestPrice":6.32,"preClose":6.31,"latestTime":"09:29 EST","volume":756,"amount":4780.42614,"timestamp":1771338599999,"change":0.01,"changeRate":0.001585,"amplitude":0.025404},"postHourTrading":{"tag":"盘后","latestPrice":6.28,"preClose":6.28,"latestTime":"16:10 EST","volume":12791,"amount":80327.48,"timestamp":1771362604707,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.867229,"impliedVol":0.4138,"impliedVolPercentile":0.0677},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":45005000,"roa":"-44.66%","roe":"-80.69%","lyrEps":-3.093449,"volumeRatio":0.867229,"shares":72987327,"dividePrice":0,"high":6.42,"amplitude":0.061807,"preClose":6.31,"low":6.03,"week52Low":1.45,"pbRate":"3.79","week52High":10.99,"institutionHeld":0,"latestPrice":6.28,"committee":-0.176471,"eps":-2.5,"divideRate":0,"volume":552212,"delay":0,"ttmEps":-2.5,"open":6.32,"prevYearClose":9.93,"prevWeekClose":6.31,"prevMonthClose":7.41,"prevQuarterClose":9.93,"fiveDayClose":7.2,"twentyDayClose":7.39,"sixtyDayClose":9.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"LXEO","fiscalQuarterEnding":"2025/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2025-08-14","symbol":"LXEO","fiscalQuarterEnding":"2025/06","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-05-12","symbol":"LXEO","fiscalQuarterEnding":"2025/03","expectedEps":-0.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5455,"buy":0.4545,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5455,"analysts":11,"updateTime":1766206800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2026-02-13","current":-2.496,"percent":0.456364,"low":-8.903248,"twenty":-6.271979,"median":-4.22602,"eighty":-2.08467,"high":-0.6043,"avg":-4.131661,"sd":2.109303,"marketCap":479526738},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153},{"date":"2025-04-25","current":-1.238984,"twenty":-6.294572,"median":-4.621669,"eighty":-2.271508,"marketCap":121832978},{"date":"2025-05-02","current":-1.590085,"twenty":-6.292966,"median":-4.546304,"eighty":-2.190247,"marketCap":156357855},{"date":"2025-05-09","current":-1.012793,"twenty":-6.292343,"median":-4.461512,"eighty":-2.110502,"marketCap":99590991},{"date":"2025-05-16","current":-0.81978,"twenty":-6.289736,"median":-4.386933,"eighty":-1.999259,"marketCap":89607702},{"date":"2025-05-23","current":-0.935157,"twenty":-6.278497,"median":-4.373941,"eighty":-1.883139,"marketCap":102219157},{"date":"2025-05-30","current":-0.871396,"twenty":-6.262715,"median":-4.292656,"eighty":-1.737224,"marketCap":95249669},{"date":"2025-06-06","current":-0.992845,"twenty":-6.24372,"median":-4.263625,"eighty":-1.61652,"marketCap":108524884},{"date":"2025-06-13","current":-2.052375,"twenty":-6.232879,"median":-4.257819,"eighty":-1.598825,"marketCap":224338921},{"date":"2025-06-20","current":-2.127645,"twenty":-6.223303,"median":-4.238865,"eighty":-1.614228,"marketCap":232566510},{"date":"2025-06-27","current":-2.06491,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"marketCap":225709077},{"date":"2025-07-03","current":-2.198289,"twenty":-6.20262,"median":-4.195762,"eighty":-1.653954,"marketCap":240288372},{"date":"2025-07-11","current":-2.267449,"twenty":-6.200163,"median":-4.140386,"eighty":-1.70361,"marketCap":247848006},{"date":"2025-07-18","current":-2.104429,"twenty":-6.198104,"median":-4.103992,"eighty":-1.718889,"marketCap":230028868},{"date":"2025-07-25","current":-1.812971,"twenty":-6.182772,"median":-4.083635,"eighty":-1.764727,"marketCap":198170410},{"date":"2025-08-01","current":-2.336608,"twenty":-6.17781,"median":-4.06594,"eighty":-1.812971,"marketCap":255407640},{"date":"2025-08-08","current":-2.198289,"twenty":-6.166096,"median":-4.041907,"eighty":-1.86404,"marketCap":240288372},{"date":"2025-08-15","current":-2.26542,"twenty":-6.156275,"median":-3.900612,"eighty":-1.87168,"marketCap":258647483},{"date":"2025-08-22","current":-2.26069,"twenty":-6.144305,"median":-3.890098,"eighty":-1.890778,"marketCap":258107509},{"date":"2025-08-29","current":-2.251231,"twenty":-6.128418,"median":-3.827824,"eighty":-1.92165,"marketCap":257027562},{"date":"2025-09-05","current":-2.35055,"twenty":-6.121976,"median":-3.799992,"eighty":-1.925602,"marketCap":268367013},{"date":"2025-09-12","current":-2.449869,"twenty":-6.107404,"median":-3.74219,"eighty":-1.93461,"marketCap":279706464},{"date":"2025-09-19","current":-2.582295,"twenty":-6.103535,"median":-3.677964,"eighty":-1.952307,"marketCap":294825733},{"date":"2025-09-26","current":-3.07416,"twenty":-6.103378,"median":-3.543091,"eighty":-1.960886,"marketCap":350983015},{"date":"2025-10-03","current":-3.16875,"twenty":-6.084882,"median":-3.508838,"eighty":-1.966064,"marketCap":361782492},{"date":"2025-10-10","current":-3.878171,"twenty":-6.074043,"median":-3.510979,"eighty":-1.967068,"marketCap":442778573},{"date":"2025-10-17","current":-4.147751,"twenty":-6.062913,"median":-3.59126,"eighty":-1.975097,"marketCap":473557083},{"date":"2025-10-24","current":-4.256529,"twenty":-6.041368,"median":-3.707936,"eighty":-1.980826,"marketCap":485976483},{"date":"2025-10-31","current":-5.750439,"twenty":-6.046619,"median":-3.744331,"eighty":-1.985047,"marketCap":656539109},{"date":"2025-11-07","current":-5.854784,"twenty":-6.046619,"median":-3.79777,"eighty":-1.986886,"marketCap":614553293},{"date":"2025-11-14","current":-6.25113,"twenty":-6.074043,"median":-3.827824,"eighty":-1.989502,"marketCap":656156069},{"date":"2025-11-21","current":-6.195502,"twenty":-6.104132,"median":-3.878171,"eighty":-2.002315,"marketCap":650317083},{"date":"2025-11-28","current":-6.856078,"twenty":-6.134773,"median":-3.890098,"eighty":-2.017382,"marketCap":719655044},{"date":"2025-12-05","current":-6.320664,"twenty":-6.150597,"median":-3.89885,"eighty":-2.031318,"marketCap":663454802},{"date":"2025-12-12","current":-6.814357,"twenty":-6.187864,"median":-3.917739,"eighty":-2.03527,"marketCap":715275804},{"date":"2025-12-19","current":-6.925612,"twenty":-6.202522,"median":-4.030982,"eighty":-2.038234,"marketCap":726953776},{"date":"2025-12-26","current":-7.342817,"twenty":-6.232879,"median":-4.056541,"eighty":-2.044162,"marketCap":770746173},{"date":"2026-01-02","current":-6.904752,"twenty":-6.267809,"median":-4.06981,"eighty":-2.050547,"marketCap":724764157},{"date":"2026-01-09","current":-6.584894,"twenty":-6.292758,"median":-4.093288,"eighty":-2.054882,"marketCap":691189986},{"date":"2026-01-16","current":-5.215069,"twenty":-6.292758,"median":-4.112303,"eighty":-2.065989,"marketCap":547404952},{"date":"2026-01-23","current":-5.340231,"twenty":-6.291928,"median":-4.144069,"eighty":-2.070307,"marketCap":560542671},{"date":"2026-01-30","current":-5.263743,"twenty":-6.288275,"median":-4.176128,"eighty":-2.074127,"marketCap":552514065},{"date":"2026-02-06","current":-4.79091,"twenty":-6.285897,"median":-4.204325,"eighty":-2.07973,"marketCap":502882683},{"date":"2026-02-13","current":-4.568401,"twenty":-6.271979,"median":-4.22602,"eighty":-2.08467,"marketCap":479526738}],"updateTime":1771344854486},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609433580","title":"Lexeo Therapeutics Announces Head of Research Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2609433580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609433580?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:04","pubTimestamp":1770329084,"startTime":"0","endTime":"0","summary":"The latest update is out from Lexeo Therapeutics, Inc. ( ($LXEO) ). On January 30, 2026, Lexeo Therapeutics, Inc. announced that it had entered int...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-announces-head-of-research-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-announces-head-of-research-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2609876625","title":"Lexeo Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Narinder Pal Bhalla","url":"https://stock-news.laohu8.com/highlight/detail?id=2609876625","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609876625?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:46","pubTimestamp":1770327968,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Narinder Pal Bhalla as the beneficial owner, serving in the role of Chief Medical Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL5fTc2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Lexeo Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Narinder Pal Bhalla","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2609582543","title":"Lexeo Therapeutics Announces Transition Compensation Agreement for Dr. Adler","url":"https://stock-news.laohu8.com/highlight/detail?id=2609582543","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609582543?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:18","pubTimestamp":1770326336,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. has announced a new compensation agreement with Dr. Adler, who has stepped down from his role as Head of Research effective February 1, 2026. Under the Transition and Consulting Agreement, Dr. Adler will provide advisory services to the company until the earlier of July 31, 2026, or termination of the agreement. He will receive up to $62,500 in monthly installments during this period, and his service-vesting equity awards will continue to vest. Additionally, Dr. Adler's deadline to exercise any vested stock options will be extended to six months following the end of the transition period. Upon completion of the transition period and execution of a supplemental release of claims, he will receive a lump sum payment of $1,000.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2plyDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2609377991","title":"Lexeo Therapeutics to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2609377991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609377991?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:30","pubTimestamp":1770294613,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with a fireside chat scheduled for Thursday, February 12, 2026, at 12:30 p.m. ET in New York, NY. The company will also join the Oppenheimer 36th Annual Healthcare Life Sciences Conference, hosting a fireside chat on Thursday, February 26, 2026, at 10:40 a.m. ET virtually. Both events will be webcast live on the Lexeo website, with replays available after the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL4V27p2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","LU2210150020.SGD","NDAQ","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","LXEO"],"gpt_icon":0},{"id":"2606787004","title":"BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787004?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:06","pubTimestamp":1769522791,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA HealthcareEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL6N3YS0NO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF417.EUR","CDE","NEE","AU","CRDF","HL","LU1064131342.USD","BA","BRO","MU","PG","LU0225283273.USD","GM","GLW","MUD","RTX","NOC","CRM","JBLU","KMB","MOH","LU0786609619.USD","UNH","UNHW","HCA","UNHG","EFC","PINS","LXEO","MUU","CVS","UPS","DDOG","LU1261432733.SGD","AAL","PUMP","IE00B1BXHZ80.USD","ELV","MULL","HUM","LU0654597011.USD","LU2317271919.USD","BK4528","NEM","LU0267386448.USD","AFRM","NET","NTLA"],"gpt_icon":0},{"id":"2606822697","title":"BUZZ-Lexeo rises as it announces leadership changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2606822697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606822697?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:31","pubTimestamp":1769520717,"startTime":"0","endTime":"0","summary":"BUZZ-Lexeo rises as it announces leadership changes** Shares of drug developer Lexeo Therapeutics LXEO.O  rise 2% to $7.63 premarket ** Co says it named cardiologist Dr. Narinder Bhalla as chief medical officer** Co says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditions** CTO José Manuel Otero moves to the chief operating officer's role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEO** Shares up ~51% in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL4N3YS1C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2606816437","title":"Press Release: Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2606816437","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606816437?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:30","pubTimestamp":1769517000,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 27, 2026  -- Lexeo Therapeutics, Inc. , a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform.Narinder Bhalla, MD has been appointed Chief Medical Officer, effective immediately. With more than two decades of experience as an interventional cardiologist and nearly a decade in biopharma leadership, Dr. Bhalla is a seasoned physician-executive who has held senior roles at AstraZeneca and, most recently, at Bristol Myers Squibb, where he served as Senior Vice President and Head of Global Medical, ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IE0009354923.USD","BK4535","RNA","R","BK4022","BK4130","BK4539","FA","LXEO","BK4082","BK4585","CSII","BK4588","BK4139","BK4232"],"gpt_icon":0},{"id":"2603389276","title":"Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2603389276","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603389276?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:37","pubTimestamp":1768315068,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Lexeo Therapeutics, Inc., with a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-inc-lxeo-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexeo-therapeutics-inc-lxeo-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2603686027","title":"Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686027?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:18","pubTimestamp":1768306680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:18 ET (12:18 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2603613683","title":"Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603613683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603613683?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:15","pubTimestamp":1768302911,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $10 from $13 and keeps a Buy rating on the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-10-from-13-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-price-target-lowered-to-10-from-13-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2603002855","title":"Raymond James Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603002855","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603002855?lang=en_us&edition=fundamental","pubTime":"2026-01-13 18:25","pubTimestamp":1768299952,"startTime":"0","endTime":"0","summary":"Raymond James analyst Christopher Raymond maintained a Buy rating on Lexeo Therapeutics, Inc. today and set a price target of $25.00. According to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-keeps-their-buy-rating-on-lexeo-therapeutics-inc-lxeo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-keeps-their-buy-rating-on-lexeo-therapeutics-inc-lxeo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","LXEO"],"gpt_icon":0},{"id":"2603154756","title":"Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2603154756","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603154756?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:19","pubTimestamp":1768238344,"startTime":"0","endTime":"0","summary":"An update from Lexeo Therapeutics, Inc. ( ($LXEO) ) is now available. On January 12, 2026, Lexeo Therapeutics reported positive interim Phase I/II ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-positive-interim-heroic-pkp2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-positive-interim-heroic-pkp2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2602544369","title":"Lexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602544369","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602544369?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:53","pubTimestamp":1768233231,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics  said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.The investigational gene therapy was \"generally well tolerated\" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.Shares of Lexeo Therapeutics fell more than 34% in recent trading Monday.Price: 6.92, Change: -3.62, Percent Change: -34.35","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602401546","title":"Lexeo Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2602401546","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602401546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:35","pubTimestamp":1768228544,"startTime":"0","endTime":"0","summary":"09:32 EST Lexeo Therapeutics (LXEO) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602546661","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:32 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602546661","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602546661?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:32","pubTimestamp":1768228370,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:32 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nAQN2LH9U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602851297","title":"Lexeo Therapeutics Unveils Cardiac Gene Therapy Pipeline Targeting Inherited Heart Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851297","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851297?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:25","pubTimestamp":1768220737,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. presented an update on its cardiac gene therapy platform, highlighting progress in the development of treatments for inherited cardiac diseases. The company’s pipeline includes LX2006 for Friedreich Ataxia Cardiomyopathy, LX2020 for PKP2 Arrhythmogenic Cardiomyopathy, LX2021 for Desmoplakin-related cardiomyopathy, and LX2022 for Hypertrophic Cardiomyopathy. Recent milestones include positive data from Phase I/II studies, completion of enrollment in the HEROIC Phase I/II study, and receipt of FDA Breakthrough Designation for LX2006. Lexeo also announced a partnership to advance novel cardiac RNA therapeutics and maintains a strong financial position with a cash runway projected into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6fN3M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602514665","title":"Lexeo Therapeutics Reports Positive Interim Results for LX2020 in PKP2-Associated Cardiomyopathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514665","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514665?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219219,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. has announced positive interim results from the ongoing HEROIC-PKP2 Phase I/II clinical trial evaluating LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy . The company reported that LX2020 was generally well tolerated among ten participants, with no clinically significant complement activation observed. Data showed dose-dependent increases in PKP2 protein expression, with a mean increase of 93% in the low-dose cohort and 162% in high-dose cohorts. The majority of participants experienced stabilization or improvement in arrhythmia burden, including non-sustained ventricular tachycardia and premature ventricular contractions. Lexeo Therapeutics plans to present 12-month data for all high-dose participants in the fourth quarter of 2026 and anticipates regulatory engagement later that year. The interim results were presented during a company webcast on January 12, 2026.Disclaimer: This news brief was created by Public Technologies  using gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9KwpwF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","LXEO","NDAQ","SG9999014039.USD","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","BK4588"],"gpt_icon":0},{"id":"2602514540","title":"Lexeo Therapeutics Announces Positive Interim Phase I/Ii Data for Lx2020 for the Treatment of Pkp2-Associated Arrhythmogenic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514540?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUABLL0NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602145165","title":"Lexeo Therapeutics Inc: Lx2020 Generally Well Tolerated Across Ten Participants With No Clinically Significant Complement Activation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602145165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602145165?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUABLL0NW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2602538285","title":"Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2602538285","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602538285?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:52","pubTimestamp":1768056773,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Lexeo Therapeutics implies that they have significant influence over...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/institutional-investors-have-a-lot-riding-on-lexeo-therapeut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/institutional-investors-have-a-lot-riding-on-lexeo-therapeut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","TSYW.SI",".IXIC","QID","QLD","TQQQ","USJW.SI","MNQmain","NVIW.SI","BK4139","USAW.SI","PSQ","LXEO","NQmain"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":74,"code":"91000000","status":"200"}]}}